

V8: Cell cycle – summary

(1) Course evaluation

(2) Content of minitest #2:

- Lecture V5 (slides 15, 16, 18-20),
- V6 (slides 1-5,8,18)
- V7 (slides 1-2,18-20)

- Specified content from Papers 4 to 6:
methods, results and discussion section related to the indicated figures.

Cell cycle checkpoints

Cell cycle **checkpoints** are control mechanisms that ensure the fidelity of cell division in eukaryotic cells.

These checkpoints verify whether the processes at each phase of the cell cycle have been accurately completed before progression into the next phase.

An important function of many checkpoints is to **assess DNA damage**, which is detected by sensor mechanisms.

When damage is found, the checkpoint uses a signal mechanism either to stall the cell cycle until **repairs** are made or, if repairs cannot be made, to target the cell for destruction via **apoptosis** (effector mechanism).

All the checkpoints that assess DNA damage appear to utilize the same sensor-signal-effector mechanism.

Is the cyclin-CDK oscillator essential?

The cyclin–CDK oscillator governs the major events of the cell cycle.

In embryonic systems this oscillator functions in the absence of transcription, relying only on maternal stockpiles of messenger RNAs and proteins.

CDKs are also thought to act as the central oscillator in somatic cells and yeast.

Orlando et al., Nature 453, 944-947 (2008)

What happens in cyclin-deletion mutants?

Plan: investigate the dynamics of genome-wide transcription in budding yeast cells that are **disrupted** for all S-phase and mitotic **cyclins** ($\Delta clb1,2,3,4,5,6$).

These cyclin-mutant cells are unable to replicate DNA, to separate spindle pole bodies, to undergo isotropic bud growth or to complete nuclear division.

-> indicates that mutant cells are devoid of functional Clb–CDK complexes.

So, by conventional cell-cycle measures, $\Delta clb1,2,3,4,5,6$ cells arrest at the G1/S border.

Expectation:

if Clb–CDK activities are essential for triggering the transcriptional program, then periodic expression of S-phase-specific and G2/M-specific genes should not be observed.

Orlando et al., Nature 453, 944-947 (2008)

Periodic transcripts in wt and cyclin-mutant cells

Aim: Identify periodically expressed genes.

For each gene, i , a Fourier score, F_i , was computed as


$$F_i = \sqrt{\left(\sum_t \sin(\omega t) \cdot x_i(t)\right)^2 + \left(\sum_t \cos(\omega t) \cdot x_i(t)\right)^2}$$

where $\omega = 2\pi/T$ and T is the interdivision time.

Similarly, scores were calculated for 1 000 000 artificial profiles constructed by random shuffling of the data points within the expression profile of the gene in question.

The P -value for periodicity was calculated as the fraction of artificial profiles with Fourier scores equal to or larger than that observed for the real expression profile.

Orlando et al., Nature 453, 944-947 (2008)



Heat maps depicting mRNA levels of 1271 periodic genes for wild-type cells.

Each row represents data for one gene.


Periodic transcripts in wt and cyclin-mutant cells

mRNA levels of periodic genes for wild-type (a) and cyclin-mutant (b) cells.

Each row in a and b represents data for the same gene.

The S and G2/M phases of the cyclin-mutant timeline are shaded.

By conventional definitions, cyclin-mutant cells arrest at the G1/S-phase border.



Observations

- (1) Expression of 883 genes is altered in the mutant (so that they are likely regulated by B-cyclin CDK,
- (2) However, although mutant cells are arrested at G1/S border, gene regulation program seems to continue ...

Orlando et al., Nature 453, 944-947 (2008)

V6: Protein phosphorylation during cell cycle

Protein **phosphorylation** and **dephosphorylation** are highly controlled biochemical processes that respond to various intracellular and extracellular stimuli.

Phosphorylation status modulates protein activity by

- influencing the tertiary and quaternary **structure** of a protein,
- controlling its **subcellular distribution**, and
- regulating its **interactions** with other proteins.

Regulatory protein phosphorylation is a **transient modification** that is often of low occupancy or “stoichiometry”

This means that only a fraction of a particular protein may be phosphorylated on a given site at any particular time, and that occurs on regulatory proteins of low abundance, such as protein kinases and transcription factors.

Olsen Science
Signaling 3 (2010)

Cell Cycle and the Phosphoproteome

CELL CYCLE

Quantitative Phosphoproteomics Reveals Widespread Full Phosphorylation Site Occupancy During Mitosis

Jesper V. Olsen,^{1,2*} Michiel Vermeulen,^{1,3*} Anna Santamaria,^{4*} Chanchal Kumar,^{1,5*} Martin L. Miller,^{2,6} Lars J. Jensen,² Florian Gnad,¹ Jürgen Cox,¹ Thomas S. Jensen,⁷ Erich A. Nigg,⁴ Søren Brunak,^{2,7} Matthias Mann^{1,2†}

(Published 12 January 2010; Volume 3 Issue 104 ra3)

www.SCIENCESIGNALING.org 12 January 2010 Vol 3 Issue 104 ra3

Aim: Analyze all proteins that are modified by phosphorylation during different stages of the cell cycle of human HeLa cells.

Ion-exchange chromatography + HPLC + MS + sequencing led to the identification of 6695 phosphorylated proteins („the phospho-proteome“). From this, 6027 quantitative cell cycle profiles were obtained.

A total of 24,714 phosphorylation events were identified. 20,443 of them were assigned to a specific residue with high confidence.

Finding: about **70%** of all proteins get phosphorylated.

Review: protein quantification by SILAC

ARTICLE

doi:10.1038/nature10098

Global quantification of mammalian gene expression control


Björn Schwanhäusser¹, Dorothea Busse¹, Na Li¹, Gunnar Dittmar¹, Johannes Schuchhardt², Jana Wolf¹, Wei Chen¹ & Matthias Selbach¹

SILAC: „stable isotope labelling by amino acids in cell culture“ means that cells are cultivated in a medium containing heavy stable-isotope versions of essential amino acids.

When non-labelled (i.e. light) cells are transferred to heavy SILAC growth medium, newly synthesized proteins incorporate the heavy label while pre-existing proteins remain in the light form.

Schwanhäuser et al. Nature 473, 337 (2011)

WS 2017/18 - lecture 6



Protein turnover is quantified by mass spectrometry and next-generation sequencing, respectively.

H/L ratios of individual proteins


Mass spectra of peptides for two proteins.

Top: **high-turnover protein**
Bottom: **low-turnover protein**.

Over time, the heavy to light (H/L) ratios increase.

H-concentration of high-turnover protein saturates.

That of low-turnover protein still increases.



This example illustrates the principles of SILAC and mass spectroscopy signals (peaks).

m/z : mass over charge ratio of a peptide fragment

In the Olson et al. study, the authors used H and L forms to label different stages of the cell cycle.

Schwanhäuser et al. Nature 473, 337 (2011)


Quantitative proteomic analysis

HeLa S3 cells were SILAC-labeled with 3 different isotopic forms (light – medium – heavy) of arginine and lysine.

3 individual populations of heavy and light SILAC cells were synchronized with a **thymidine** block (analog of thymine, blocks entry into S phase).


Cells were then collected at 6 different time points across the cell cycle after release from the **thymidine arrest**.

Out of this, 2 samples were collected after a further **cell cycle arrest** with **nocodazole** and release. (Nocodazole interferes with polymerization of microtubules.)





Center: asynchronously growing cell population as internal standard to allow normalization between experiments.

Experiment 1: mixture of
 L = G1 phase
 M = Async
 H = S phase




Monitor protein abundance by MS



Representative MS data showing how the abundance of the proteins was monitored in 3 experiments to obtain information from the 6 stages of the cell cycle.


The data show the MS analysis of a tryptic SILAC peptide triplet derived from the cell cycle marker protein **Geminin**.

Relative peptide abundance changes were normalized to the medium SILAC peptide derived from the asynchronously grown cells in all three experiments. The inset of Exp. 1 shows the combined six-time profile of Geminin over the cell cycle.



Example: Dynamic phosphorylation of CDK1

CDK1 phosphorylation site kinetics



Dynamic profile of two CDK1 phosphopeptides during the cell cycle.

The activating site Thr161 (red) peaks in mitosis, whereas phosphorylation of the inhibitory sites Thr14 and Tyr15 (blue) is decreased in mitosis


Olsen Science
Signaling 3 (2010)

V7: CDK inhibitors

Cancer is characterized by **aberrant cell cycle activity**.

This occurs either as result of **mutations** in **upstream signaling pathways** or by **genetic lesions** within genes encoding cell cycle proteins.

Aberrant activation of CDKs, which is frequently seen in human cancers, provided a rationale for designing synthetic inhibitors of CDKs as anticancer drugs.



A dividing cancer cell.

<http://www.nature.com/articles/nrd4504> (2015)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345933/>

<http://science.sciencemag.org/content/345/6199/865.full>

Mol Cancer Ther **15** 2273-2281 (2016)

Review: Progression of the human cell cycle driven by CDKs


Mitogenic signals

stimulate CDK4 and CDK6 and promote entry into the cell cycle.

In contrast,

antiproliferative

checkpoints inhibit CDK4 and CDK6 activity or induce the expression of the CDK4 and CDK6 inhibitor **p16^{INK4A}** (compare lecture V5, p.12).




<http://www.nature.com/articles/nrd4504>

Cdk phosphorylation events in Rb

Sites	Domain	Structural Effect	Biochemical Output
S249/T252	RbN	Unknown	Inhibits protein interactions with RbN
T356	RbIDL	C-terminal helix of RbN becomes disordered	Unknown
T373	RbIDL	Nucleates N-terminal pocket helix to induce RbN-pocket association	Inhibits E2F ^{TD} and LxCxE binding to pocket domain
S608/S612	RbL	RbL binds pocket	Inhibits E2F ^{TD} binding
S780	Pocket	Unknown	Unknown
S788/S795	RbC	Unknown	Inhibits RbC-E2F1 ^{MB} -UP ^{MB} binding
S807/S811	RbC	Unknown	Might prime phosphorylation at other sites
T821/T826	RbC	Induces RbC binding to the pocket domain	Inhibits RbC-E2F1 ^{MB} -DP ^{MB} binding and inhibits LxCxE binding to pocket domain.

Trends Biochem Sci. 2013 Jan; 38(1): 12–19.

Deregulation of CDK regulatory genes in cancer.





Frequencies of genetic amplification of *CDK4* and *CDK6* across multiple disease sites.

The frequencies of mutation (green), amplification (red) and homozygous deletion (dark blue) were determined using genetic data from >2,000 cancer cases.

Different types of cancer exhibit distinct predominant mechanisms of genetic alterations in cell cycle control.

<http://www.nature.com/articles/nrd4504>


Deregulation of CDK regulatory genes in cancer.




<http://www.nature.com/articles/nrd4504>

Deregulation of CDK regulatory genes in cancer.

CDKN2A cyclin-dependent kinase inhibitor 2A („inhibitors are shut down by deletion“)







CCNE1 and CCNE2 cyclins E1 and E2 („activators are amplified“)



<http://www.nature.com/articles/nrd4504>


Content from paper 4 that is relevant for mini test #2

ONLY: methods and results related to Figs 1, 2, 3




Content from paper 5 that is relevant for mini test #2

ONLY: methods and results related to Figs 1 and 2




SS 2019 - lecture 3



Cellular programs

Content from paper 6 that is relevant for mini test #2

ONLY: methods and results related to Figs 2 and 3



Subgroup		Events, n/N (%)		Favors ribociclib	Favors placebo	Hazard ratio	95% CI
		Ribociclib plus fulvestrant	Placebo plus fulvestrant				
All patients		210/484 (43)	151/242 (62)			0.593	0.480 to 0.732
Prior endocrine therapy*	Treatment naïve	76/238 (32)	66/129 (51)			0.577	0.415 to 0.802
	Up to one line	131/236 (56)	84/109 (77)			0.565	0.428 to 0.744
Liver or lung involvement	Yes	116/242 (48)	77/121 (64)			0.645	0.483 to 0.861
	No	94/242 (39)	74/120 (62)			0.563	0.415 to 0.764
Bone lesion only	Yes	36/103 (35)	35/51 (69)			0.379	0.234 to 0.613
	No	174/381 (46)	116/190 (61)			0.658	0.519 to 0.833
Age, years	< 65	115/258 (45)	81/129 (63)			0.607	0.454 to 0.810
	≥ 65	95/226 (42)	70/113 (62)			0.597	0.436 to 0.818
Race	Asian	22/45 (49)	7/18 (39)			1.353	0.574 to 3.186
	White	174/406 (43)	136/213 (64)			0.562	0.448 to 0.704
	Other	8/18 (44)	3/6 (50)			0.881	0.199 to 3.907
ECOG PS	0	126/310 (41)	95/158 (60)			0.559	0.427 to 0.733
	1	83/173 (48)	56/83 (67)			0.633	0.450 to 0.890
No. of metastatic sites	< 3	126/309 (41)	92/149 (62)			0.586	0.447 to 0.768
	≥ 3	84/175 (48)	59/92 (64)			0.621	0.441 to 0.874
Prior tamoxifen	Yes	79/193 (41)	63/104 (61)			0.620	0.443 to 0.866
	No	131/291 (45)	88/137 (64)			0.562	0.428 to 0.738
Prior AI	Yes	135/257 (53)	80/118 (68)			0.670	0.507 to 0.886
	No	75/227 (33)	71/123 (58)			0.481	0.345 to 0.669

Hazard ratio (95% CI)